Published in Immunotargets Ther on May 28, 2015
Impact of Metabolism on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment. Front Immunol (2017) 0.75
Forsythoside A Inhibits BVDV Replication via TRAF2-Dependent CD28-4-1BB Signaling in Bovine PBMCs. PLoS One (2016) 0.75
CD28 days later: Resurrecting costimulation for CD8(+) memory T cells. Eur J Immunol (2016) 0.75
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev (2006) 10.24
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 6.65
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity (1995) 5.77
Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol (2007) 5.62
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science (1991) 5.12
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell (2000) 4.10
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci U S A (2002) 3.28
Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol (2008) 3.23
CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev (2009) 3.09
Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol (1999) 2.77
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76
Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev (2006) 2.71
Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature (2002) 2.71
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 2.71
CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol (2009) 2.66
Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med (1996) 2.60
Properties of mouse and human IgG receptors and their contribution to disease models. Blood (2012) 2.53
Crystal structure of a soluble CD28-Fab complex. Nat Immunol (2005) 2.46
The interaction properties of costimulatory molecules revisited. Immunity (2002) 2.43
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol (2011) 2.36
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci U S A (2002) 2.32
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med (2009) 2.23
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood (2011) 2.12
Continuous requirement for the TCR in regulatory T cell function. Nat Immunol (2014) 2.11
Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum (1997) 2.11
Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice. Stroke (2014) 2.06
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology (2011) 2.03
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96
Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol (2011) 1.93
CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol Cell Biol (1997) 1.83
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med (2005) 1.79
CD28 costimulation promotes the production of Th2 cytokines. J Immunol (1997) 1.78
CTLA4Ig: bridging the basic immunology with clinical application. Immunity (2006) 1.75
Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med (2003) 1.70
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol (1996) 1.69
Cell-intrinsic and -extrinsic control of Treg-cell homeostasis and function revealed by induced CD28 deletion. Eur J Immunol (2012) 1.66
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol (2010) 1.65
The role of CTLA-4 in regulating Th2 differentiation. J Immunol (1999) 1.62
Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol (2014) 1.61
The reverse stop-signal model for CTLA4 function. Nat Rev Immunol (2008) 1.60
The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev (2009) 1.58
The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol (2000) 1.54
Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol (2010) 1.47
CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J Immunol (2007) 1.37
CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol (2000) 1.34
Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo. Eur J Immunol (1999) 1.32
An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol (2010) 1.30
Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res (2014) 1.30
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol (2007) 1.29
Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest (1995) 1.27
Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J Immunol (1991) 1.23
Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med (2010) 1.17
B7-h2 is a costimulatory ligand for CD28 in human. Immunity (2011) 1.17
Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling. J Biol Chem (2008) 1.15
CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest (2004) 1.14
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol (2010) 1.11
Sustained CD28 expression delays multiple features of replicative senescence in human CD8 T lymphocytes. J Clin Immunol (2010) 1.10
An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J Immunol (2001) 1.09
The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09
Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo. J Immunol (2011) 1.08
Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J Immunol (2007) 1.08
T cell antigen receptor activation and actin cytoskeleton remodeling. Biochim Biophys Acta (2013) 1.03
Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant (2011) 1.02
CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol (2008) 1.02
p27Kip1 regulates T cell proliferation. J Biol Chem (2001) 1.02
Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation. Proc Natl Acad Sci U S A (2007) 1.02
Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Lett (2010) 1.01
Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses. J Immunol (2006) 1.00
CD4+CD25+ regulatory T cells are activated in vivo by recognition of self. Int Immunol (2007) 0.99
Protection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody. Blood (2008) 0.99
CD28 signals through acidic sphingomyelinase. J Exp Med (1995) 0.98
Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant (2012) 0.96
Mitogenic signals through CD28 activate the protein kinase Ctheta-NF-kappaB pathway in primary peripheral T cells. Int Immunol (2003) 0.96
Cutting edge: distinct TCR- and CD28-derived signals regulate CD95L, Bcl-xL, and the survival of primary T cells. J Immunol (2004) 0.90
A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int (2010) 0.89
Two pathways of costimulation through CD28. Immunol Res (2009) 0.88
Therapeutic use of anti-CTLA-4 antibodies. Int Immunol (2014) 0.88
CD28 costimulation regulates FOXP3 in a RelA/NF-κB-dependent mechanism. Eur J Immunol (2011) 0.87
Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo. J Immunol (2011) 0.85
Unlike CD4+ T-cell help, CD28 costimulation is necessary for effective primary CD8+ T-cell influenza-specific immunity. Eur J Immunol (2012) 0.85
Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation (1999) 0.85
Autonomous induction of proliferation, JNK and NF-alphaB activation in primary resting T cells by mobilized CD28. Eur J Immunol (2000) 0.82
Neutral sphingomyelinase in physiological and measles virus induced T cell suppression. PLoS Pathog (2014) 0.81
T cell receptor signaling can directly enhance the avidity of CD28 ligand binding. PLoS One (2014) 0.81
Cutting edge: A role for inside-out signaling in TCR regulation of CD28 ligand binding. J Immunol (2011) 0.81
Lack of costimulation by both sphingomyelinase and C2 ceramide in resting human T cells. Immunology (2000) 0.81
Belatacept in kidney transplantation. Curr Opin Organ Transplant (2012) 0.80
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol (2007) 1.29
CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke. J Cereb Blood Flow Metab (2014) 0.87
Novel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat model. PLoS One (2015) 0.81
In vitro polyclonal activation of conventional T cells with a CD28 superagonist protects mice from acute graft versus host disease. Eur J Immunol (2015) 0.80
The hypervariable region 4 (HV4) and position 93 of the α chain modulate CD1d-glycolipid binding of iNKT TCRs. Eur J Immunol (2015) 0.80
Interrupting CD28 costimulation before antigen rechallenge affects CD8(+) T-cell expansion and effector functions during secondary response in mice. Eur J Immunol (2016) 0.77
T-cell receptor signaling activates an ITK/NF-κB/GATA-3 axis in T-cell lymphomas facilitating resistance to chemotherapy. Clin Cancer Res (2016) 0.75
Targeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination. Cancer Immunol Immunother (2016) 0.75
Short-term cytokine stimulation reveals regulatory T-cells with down-regulated Foxp3 expression in human peripheral blood. Eur J Immunol (2017) 0.75
Protection of Mice from Acute Graft-versus-Host Disease Requires CD28 Co-stimulation on Donor CD4(+) Foxp3(+) Regulatory T Cells. Front Immunol (2017) 0.75